Updated NETs Clinical Trials
Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
-
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Conditions:  Advanced Extrapulmonary Neuroendocrine Carcinoma;  Metastatic Extrapulmonary Neuroendocrine Carcinoma;  Recurrent Extrapulmonary Neuroendocrine Carcinoma;  Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions:  Biological: Atezolizumab;  Procedure: Biospecimen Collection;  Drug: Carboplatin;  Drug: Cisplatin;  Procedure: Computed Tomography;  Drug: Etoposide;  Procedure: Magnetic Resonance Imaging;  Other: Patient Observation
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Condition:  Neuroendocrine Tumors
Interventions:  Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT;  Drug: CAPTEM (Capecitabine and Temozolomide);  Other: Amino-Acid Solution;  Drug: Everolimus;  Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Sponsor:  ITM Solucin GmbH
Recruiting -
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Conditions:  VHL Pancreatic Neuroendocrine Tumors;  Von Hippel-Lindau Disease;  Neuroendocrine Tumors
Intervention:  Drug: 68-Gallium DOTATATE
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
Condition:  Metastatic Neuroendocrine Tumor
Interventions:  Procedure: Biospecimen Collection;  Procedure: Computed Tomography;  Drug: Lutetium Lu 177 Dotatate;  Procedure: Magnetic Resonance Imaging;  Drug: Triapine
Sponsor:  National Cancer Institute (NCI)
Recruiting -
A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
Condition:  Advanced Neuroendocrine Carcinoma
Interventions:  Drug: Surufatinib plus Toripalimab;  Drug: 5-fluorouracil, Calcium folinate and Irinotecan
Sponsor:  Hutchison Medipharma Limited
Recruiting -
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas
Conditions:  Neuroendocrine Carcinoma;  Digestive Cancer
Interventions:  Drug: Neoadjuvant treatment;  Drug: Adjuvant treatment
Sponsors:  GERCOR - Multidisciplinary Oncology Cooperative Group;  Fondation ARCAD
Recruiting -
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Conditions:  Advanced Lung Carcinoid Tumor;  Functioning Lung Carcinoid Tumor;  Locally Advanced Lung Neuroendocrine Neoplasm;  Lung Atypical Carcinoid Tumor;  Lung Neuroendocrine Neoplasm;  Lung Typical Carcinoid Tumor;  Metastatic Lung Carcinoid Tumor;  Metastatic Lung Neuroendocrine Neoplasm;  Non-Functioning Lung Carcinoid Tumor;  Recurrent Lung Neuroendocrine Neoplasm;  Unresectable Lung Carcinoid Tumor;  Unresectable Lung Neuroendocrine Neoplasm
Interventions:  Drug: Everolimus;  Drug: Lutetium Lu 177 Dotatate
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Conditions:  EGFR-Mutated Non-Small-Cell Lung Carcinoma;  Small Cell/Neuroendocrine
Interventions: Â Drug:Â Olaparib; Â Drug:Â Durvalumab
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Conditions:  Small Cell Neuroendocrine Carcinoma;  Prostate Cancer;  Small Cell Carcinoma
Interventions: Â Drug:Â Apalutamide; Â Biological:Â Cetrelimab
Sponsors:  Rahul Aggarwal;  Janssen Scientific Affairs, LLC
Recruiting -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions:  Atypical Carcinoid Tumor;  Carcinoid Tumor;  Functioning Pancreatic Neuroendocrine Tumor;  Intermediate Grade Lung Neuroendocrine Neoplasm;  Locally Advanced Digestive System Neuroendocrine Neoplasm;  Locally Advanced Digestive System Neuroendocrine Tumor G1;  Locally Advanced Lung Neuroendocrine Neoplasm;  Locally Advanced Pancreatic Neuroendocrine Tumor;  Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;  Low Grade Lung Neuroendocrine Neoplasm;  Lung Atypical Carcinoid Tumor;  Lung Carcinoid Tumor;  Metastatic Digestive System Neuroendocrine Neoplasm;  Metastatic Digestive System Neuroendocrine Tumor G1;  Metastatic Lung Carcinoid Tumor;  Metastatic Lung Neuroendocrine Neoplasm;  Metastatic Pancreatic Neuroendocrine Neoplasm;  Metastatic Pancreatic Neuroendocrine Tumor;  Metastatic Thymic Neuroendocrine Neoplasm;  Neuroendocrine Neoplasm;  Non-Functioning Pancreatic Neuroendocrine Tumor;  Pancreatic Serotonin-Producing Neuroendocrine Tumor;  Thymic Carcinoid Tumor;  Unresectable Digestive System Neuroendocrine Neoplasm;  Unresectable Digestive System Neuroendocrine Tumor G1;  Unresectable Lung Neuroendocrine Neoplasm;  Unresectable Pancreatic Neuroendocrine Neoplasm;  Unresectable Thymic Neuroendocrine Neoplasm
Interventions:  Drug: Cabozantinib S-malate;  Procedure: Computed Tomography;  Procedure: Magnetic Resonance Imaging;  Other: Placebo Administration;  Other: Quality-of-Life Assessment;  Procedure: X-Ray Imaging
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
Conditions:  Metastatic Midgut Neuroendocrine Tumor;  Unresectable Midgut Neuroendocrine Tumor
Interventions:  Procedure: Biospecimen Collection;  Procedure: Computed Tomography;  Drug: Everolimus;  Drug: Lutetium Lu 177 Dotatate;  Other: Quality-of-Life Assessment;  Other: Questionnaire Administration
Sponsor:  National Cancer Institute (NCI)
Not yet recruiting -
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Conditions:  Pheochromocytoma/Paraganglioma;  Pancreatic Neuroendocrine Tumor;  Von Hippel-Lindau Disease;  Advanced Gastrointestinal Stromal Tumor;  HIF-2α Mutated Cancers
Intervention: Â Drug:Â Belzutifan
Sponsor:  Merck Sharp & Dohme LLC
Recruiting -
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
Condition:  Neuroendocrine Carcinoma
Intervention:  Drug: Surufatinib and Serplulimab
Sponsor:  Wuhan Union Hospital, China
Not yet recruiting -
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Conditions:  Gastroenteropancreatico Tumors;  Neuroendocrine Tumors;  Neuroendocrine Neoplasms
Interventions:  Drug: Lu-177-DOTATATE;  Drug: Olaparib;  Diagnostic Test: Ga dotatate scanning;  Diagnostic Test: FDG-PET scanning;  Drug: Amino Acid infusion
Sponsor:  National Cancer Institute (NCI)
Recruiting -
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
Conditions:  Prostate Cancer;  Neuroendocrine Tumors;  Small Cell Carcinoma
Interventions:  Drug: BXCL701 plus Pembrolizumab;  Drug: BXCL701 monotherapy
Sponsor:  BioXcel Therapeutics Inc
Recruiting -
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
Conditions:  Advanced Adrenal Gland Pheochromocytoma;  Advanced Paraganglioma;  Metastatic Adrenal Gland Pheochromocytoma;  Metastatic Paraganglioma;  Unresectable Adrenal Gland Pheochromocytoma;  Unresectable Paraganglioma
Interventions:  Drug: Olaparib;  Other: Quality-of-Life Assessment;  Drug: Temozolomide
Sponsor:  National Cancer Institute (NCI)
Recruiting -
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Conditions:  HRD Cancer;  SCLC;  Advanced Solid Tumors
Interventions:  Drug: Berzosertib;  Drug: Sacituzumab Govitecan
Sponsor:  National Cancer Institute (NCI)
Recruiting -
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
Conditions:  Lung Neuroendocrine Neoplasm;  GEP Neuroendocrine Tumor
Intervention:  Drug: Cabozantinib and Temozolomide
Sponsor:  National Cancer Institute, Naples
Recruiting -
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Conditions:  Advanced Solid Tumor;  Metastatic Solid Tumor;  Urothelial Cancer;  Poorly Differentiated Neuroendocrine Carcinomas;  Homologous Recombination Deficient-Positive Malignancies Agnostic
Intervention: Â Drug:Â Lurbinectedin
Sponsor:  Jazz Pharmaceuticals
Recruiting -
Study of Oral MRT-2359 in Selected Cancer Patients
Conditions:  NSCLC;  SCLC;  High Grade Neuroendocrine Cancer;  DLBCL;  L-MYC and N-MYC Amplified Solid Tumors;  NSCLC With High or Low L-MYC or N-MYC Expression;  SCLC With High or Low L-MYC or N-MYC Expression
Intervention:  Drug: Oral MRT-2359
Sponsor:  Monte Rosa Therapeutics, Inc
Recruiting -
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Conditions:  Solid Tumor;  Non Small Cell Lung Cancer;  Neuroendocrine Carcinoma
Interventions:  Biological: VSV-IFNβ-NIS;  Biological: Pembrolizumab
Sponsors:  Vyriad, Inc.;  Mayo Clinic
Recruiting -
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Conditions:  Pheochromocytoma;  Paraganglioma;  Neuroendocrine Tumors;  Neuroendocrine Neoplasms
Interventions:  Drug: Lu-177-DOTATATE;  Drug: Ga-68-DOTATATE;  Drug: F-18-FDG;  Drug: Amino Acid solution
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Hyperbaric Oxygenation (HBO) in Traumatic Spinal Cord Injury. (EOS) - Pilot Study
Condition:  Traumatic Injury of the Spinal Cord
Intervention: Â Drug:Â HBO
Sponsor:  Medical University of Graz
Recruiting -
A Study of the Effects of Oxytocin in Adults With Obesity and Binge-eating Disorder
Condition:  Binge-eating Disorder
Interventions:  Drug: TNX-1900 (Tonix Pharmaceuticals);  Drug: Placebo
Sponsor:  Massachusetts General Hospital
Recruiting -
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Conditions:  Bladder Adenocarcinoma;  Bladder Clear Cell Adenocarcinoma;  Bladder Mixed Adenocarcinoma;  Bladder Neuroendocrine Carcinoma;  Bladder Small Cell Neuroendocrine Carcinoma;  Bladder Squamous Cell Carcinoma;  Chromophobe Renal Cell Carcinoma;  Collecting Duct Carcinoma;  Invasive Bladder Giant Cell Urothelial Carcinoma;  Invasive Bladder Lymphoepithelioma-Like Carcinoma;  Invasive Bladder Nested Urothelial Carcinoma;  Invasive Bladder Plasmacytoid Urothelial Carcinoma;  Invasive Bladder Sarcomatoid Urothelial Carcinoma;  Invasive Bladder Urothelial Carcinoma;  Kidney Medullary Carcinoma;  Large Cell Neuroendocrine Carcinoma;  Malignant Testicular Leydig Cell Tumor;  Malignant Testicular Sertoli Cell Tumor;  Metastatic Bladder Carcinoma;  Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma;  Metastatic Bladder Giant Cell Urothelial Carcinoma;  Metastatic Bladder Large Cell Neuroendocrine Carcinoma;  Metastatic Bladder Lipid-Rich Urothelial Carcinoma;  Metastatic Bladder Micropapillary Urothelial Carcinoma;  Metastatic Bladder Plasmacytoid Urothelial Carcinoma;  Metastatic Bladder Sarcomatoid Urothelial Carcinoma;  Metastatic Bladder Small Cell Neuroendocrine Carcinoma;  Metastatic Bladder Squamous Cell Carcinoma;  Metastatic Chromophobe Renal Cell Carcinoma;  Metastatic Kidney Medullary Carcinoma;  Metastatic Malignant Genitourinary System Neoplasm;  Metastatic Papillary Renal Cell Carcinoma;  Metastatic Penile Carcinoma;  Metastatic Prostate Small Cell Neuroendocrine Carcinoma;  Metastatic Sarcomatoid Renal Cell Carcinoma;  Metastatic Urethral Carcinoma;  Papillary Renal Cell Carcinoma;  Sarcomatoid Renal Cell Carcinoma;  Stage IV Bladder Cancer AJCC v8;  Stage IV Penile Cancer AJCC v8;  Stage IV Renal Cell Cancer AJCC v8;  Stage IV Urethral Cancer AJCC v8;  Stage IVB Prostate Cancer AJCC v8;  Urachal Adenocarcinoma;  Urethral Clear Cell Adenocarcinoma
Interventions:  Procedure: Bone Scan;  Drug: Cabozantinib S-malate;  Procedure: Computed Tomography;  Biological: Ipilimumab;  Procedure: Magnetic Resonance Imaging;  Biological: Nivolumab;  Procedure: Positron Emission Tomography
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Conditions:  Aggressive Variant Prostate Carcinoma;  Castration-Resistant Prostate Carcinoma;  Metastatic Prostate Carcinoma;  Metastatic Prostate Neuroendocrine Carcinoma;  Metastatic Prostate Small Cell Carcinoma;  Stage IV Prostate Cancer AJCC v8
Interventions: Â Drug:Â Cabazitaxel; Â Drug:Â Carboplatin; Â Biological:Â Cetrelimab; Â Drug:Â Niraparib
Sponsors:  M.D. Anderson Cancer Center;  Janssen Pharmaceutica
Recruiting -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
Conditions:  Appendix Carcinoma;  Colon Carcinoma;  Esophageal Carcinoma;  Gastric Carcinoma;  Liver and Intrahepatic Bile Duct Carcinoma;  Malignant Digestive System Neoplasm;  Pancreatic Carcinoma;  Rectal Carcinoma;  Small Intestinal Carcinoma;  Anal Carcinoma;  Digestive System Carcinoma;  Digestive System Neuroendocrine Tumor;  Pancreatic Neuroendocrine Tumor
Interventions:  Procedure: Acupuncture Therapy;  Procedure: Acupressure Therapy;  Procedure: Oral Cryotherapy;  Other: Questionnaire Administration;  Other: Quality-of-Life Assessment
Sponsors:  University of Washington;  National Cancer Institute (NCI);  The Safeway Foundation
Recruiting -
Non-Viral TCR Gene Therapy
Conditions:  Endocrine/Neuroendocrine;  Non-Small Cell Lung Cancer;  Breast Cancer;  Gastrointestinal/Genitourinary Cancers;  Ovarian Cancer
Interventions:  Drug: Fludarabine;  Drug: Cyclophosphamide;  Drug: Aldesleukin;  Biological: Sleeping Beauty Transposed PBL
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Conditions:  Endocrine Tumors;  Non-Small Cell Lung Cancer;  Ovarian Cancer;  Breast Cancer;  Gastrointestinal/Genitourinary Cancers;  Neuroendocrine Tumors;  Multiple Myeloma
Interventions:  Drug: Cyclophosphamide;  Drug: Fludarabine;  Drug: Aldesleukin;  Biological: Individual Patient TCR-Transduced PBL;  Drug: Pembrolizumab (KEYTRUDA )
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Conditions:  Pancreatic Cancer;  Pancreas Cancer;  Ampullary Cancer;  Pancreas Neuroendocrine Tumor;  Pancreatitis;  Distal Extrahepatic Cholangiocarcinoma;  Duodenal Cancer
Interventions: Â Drug:Â Placebo; Â Drug:Â Pantoprazole
Sponsor:  Washington University School of Medicine
Recruiting -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Conditions:  Colorectal Cancer Not MSI-H or MMR-deficient;  GIST;  Oesophageal or Gastric Carcinoma;  Biliary Tract Cancer;  Hepatocellular Carcinoma;  Soft-tissue Sarcoma;  Thyroid Cancer;  Gastro-enteropancreatic Neuroendocrine Tumor;  Non-small Cell Lung Cancer;  Solid Tumor, Adult;  Urothelial Carcinoma;  HPV-Related Carcinoma;  Triple Negative Breast Cancer;  Renal Carcinoma;  Mesotheliomas Pleural
Interventions:  Drug: Phase 1 : Regorafenib;  Drug: Phase 1 : Avelumab;  Drug: Phase 2 : Regorafenib;  Drug: Phase 2 : Avelumab;  Drug: Phase 2: low-dose Regorafenib
Sponsors:  Institut Bergonié;  Bayer;  Merck KGaA, Darmstadt, Germany
Recruiting -
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
Condition:  Medullary Thyroid Cancer
Interventions: Â Drug:Â Pralsetinib; Â Drug:Â Cabozantinib; Â Drug:Â Vandetanib
Sponsor:  Hoffmann-La Roche
Recruiting -
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Condition:  Medullary Thyroid Cancer
Interventions: Â Drug:Â Selpercatinib; Â Drug:Â Cabozantinib; Â Drug:Â Vandetanib
Sponsors:  Loxo Oncology, Inc.;  Eli Lilly and Company
Recruiting -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Conditions:  Advanced Cancer;  Anal Carcinoma;  Anal Cancer;  Biliary Cancer;  Cholangiocarcinoma;  Bile Duct Cancer;  Neuroendocrine Tumor;  Carcinoid Tumor;  Endometrial Carcinoma;  Endometrial Cancer;  Cervical Carcinoma;  Cervical Cancer;  Vulvar Carcinoma;  Vulvar Cancer;  Small Cell Lung Carcinoma;  Small Cell Lung Cancer (SCLC);  Mesothelioma;  Thyroid Carcinoma;  Thyroid Cancer;  Salivary Gland Carcinoma;  Salivary Gland Cancer;  Salivary Cancer;  Parotid Gland Cancer;  Advanced Solid Tumors;  Colorectal Carcinoma
Intervention: Â Biological:Â pembrolizumab
Sponsor:  Merck Sharp & Dohme LLC
Recruiting -
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Conditions:  Carcinoid Syndrome;  Carcinoid;  Carcinoid Tumor;  Carcinoid Tumor of Ileum;  Carcinoid Tumor of Cecum;  Carcinoid Syndrome Diarrhea;  Carcinoid Intestine Tumor;  Carcinoid Tumor of Liver;  Carcinoid Tumor of Pancreas
Interventions:  Drug: Randomized: 40 mg Paltusotine;  Drug: Randomized: 80 mg Paltusotine
Sponsor:  Crinetics Pharmaceuticals Inc.
Recruiting -
Study in Patients With Advanced Cancers Associated With Expression of DLL3
Condition:  Small-cell Lung Cancer
Interventions: Â Drug:Â HPN328; Â Drug:Â Atezolizumab
Sponsor:  Harpoon Therapeutics
Recruiting -
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Conditions:  Non-Small Cell Lung Cancer;  Medullary Thyroid Cancer;  Colon Cancer;  Any Solid Tumor
Intervention: Â Drug:Â LOXO-292
Sponsors:  Loxo Oncology, Inc.;  Eli Lilly and Company
Recruiting -
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Condition:  Metastatic Castration-Resistant Prostate Cancer
Interventions:  Biological: Pembrolizumab 200 mg;  Drug: Olaparib 400 mg;  Drug: Docetaxel 75 mg/m^2;  Drug: Prednisone 5 mg;  Drug: Enzalutamide 160 mg;  Other: Dexamethasone 8 mg;  Drug: Olaparib 300 mg;  Drug: Abiraterone acetate 1000 mg;  Drug: Lenvatinib;  Biological: Pembrolizumab/Vibostolimab coformulation;  Drug: Carboplatin;  Drug: Etoposide;  Biological: Belzutifan 120mg
Sponsor:  Merck Sharp & Dohme LLC
Recruiting -
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Conditions:  Atypical Teratoid/Rhabdoid Tumor;  Epithelioid Sarcoma;  Kidney Medullary Carcinoma;  Malignant Solid Neoplasm;  Poorly Differentiated Chordoma;  Recurrent Atypical Teratoid/Rhabdoid Tumor;  Recurrent Chordoma;  Recurrent Epithelioid Sarcoma;  Recurrent Kidney Medullary Carcinoma;  Recurrent Malignant Solid Neoplasm;  Recurrent Rhabdoid Tumor;  Refractory Atypical Teratoid/Rhabdoid Tumor;  Refractory Chordoma;  Refractory Epithelioid Sarcoma;  Refractory Kidney Medullary Carcinoma;  Refractory Malignant Solid Neoplasm;  Refractory Rhabdoid Tumor;  Rhabdoid Tumor
Interventions:  Biological: Atezolizumab;  Procedure: Biospecimen Collection;  Procedure: Computed Tomography;  Other: Fludeoxyglucose F-18;  Procedure: Magnetic Resonance Imaging;  Procedure: Positron Emission Tomography;  Biological: Tiragolumab;  Procedure: X-Ray Imaging
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study
Conditions:  Adrenal Gland Pheochromocytoma;  Hematopoietic and Lymphoid System Neoplasm;  Malignant Solid Neoplasm;  Paraganglioma
Interventions:  Procedure: Computed Tomography;  Drug: Talazoparib;  Drug: Temozolomide
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study
Conditions:  Advanced Renal Cell Carcinoma;  Chromophobe Renal Cell Carcinoma;  Clear Cell Renal Cell Carcinoma;  Collecting Duct Carcinoma;  Kidney Medullary Carcinoma;  Metastatic Malignant Neoplasm in the Bone;  Papillary Renal Cell Carcinoma;  Stage IV Renal Cell Cancer AJCC v8;  Unclassified Renal Cell Carcinoma
Interventions:  Drug: Cabozantinib S-malate;  Other: Quality-of-Life Assessment;  Other: Questionnaire Administration;  Radiation: Radium Ra 223 Dichloride
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Condition:  Neurofibromatosis Type 2
Interventions: Â Drug:Â REC-2282; Â Drug:Â Placebo
Sponsor:  Recursion Pharmaceuticals Inc.
Recruiting -
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
Conditions:  Hepatocellular Carcinoma;  Squamous Cell Carcinoma of the Lung;  Merkel Cell Carcinoma;  Myxoid/Round Cell Liposarcoma
Intervention: Â Biological:Â CAR-GPC3Â TÂ Cells
Sponsors:  SOTIO, LLC;  SOTIO Biotech
Recruiting -
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Condition:  Merkel Cell Carcinoma
Interventions: Â Drug:Â KRT-232; Â Drug:Â Avelumab
Sponsor:  Kartos Therapeutics, Inc.
Recruiting -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
Conditions:  Metastatic Cancer;  Foregut Carcinoid Tumor;  Gastric Adenocarcinoma;  Gallbladder Adenocarcinoma;  Liver Cancer;  GI Cancer;  GI Carcinoma;  Lung Cancer
Interventions:  Drug: Standard of Care Chemotherapy;  Procedure: Video-Assisted Thoracic Surgery (VATS);  Procedure: Lobectomy;  Radiation: Consolidative Radiation;  Radiation: Ablation Treatment;  Procedure: Resection or Excision;  Procedure: Peritonectomy;  Other: Transarterial Radioembolization
Sponsor:  University of Chicago
Not yet recruiting -
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Conditions:  Central Nervous System Nongerminomatous Germ Cell Tumor;  Choriocarcinoma;  Embryonal Carcinoma;  Immature Teratoma;  Malignant Teratoma;  Mixed Germ Cell Tumor;  Pineal Region Germ Cell Tumor;  Pineal Region Immature Teratoma;  Pineal Region Yolk Sac Tumor;  Suprasellar Germ Cell Tumor
Interventions:  Drug: Carboplatin;  Drug: Etoposide;  Biological: Filgrastim;  Drug: Ifosfamide;  Drug: Mesna;  Biological: Pegfilgrastim;  Procedure: Peripheral Blood Stem Cell Transplantation;  Other: Questionnaire Administration;  Radiation: Radiation Therapy;  Procedure: Second-Look Surgery;  Drug: Thiotepa
Sponsors:  Children's Oncology Group;  National Cancer Institute (NCI)
Recruiting